Suggested remit: To appraise the clinical and cost effectiveness of tenecteplase within its marketing authorisation for thrombolytic treatment of acute ischaemic stroke.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6306

Provisional Schedule

Expected publication 24 July 2024

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Stakeholders

Companies sponsors Boehringer Ingelheim (tenecteplase)
Others Department of Health and Social Care
  NHS England
Patient carer groups None
Professional groups Association of British Neurologists
  British and Irish Association of Stroke Physicians
  Royal College of Physicians
Associated public health groups None
Comparator companies Boehringer Ingelheim (alteplase) (confidentiality agreement signed, participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
28 June 2024 - 12 July 2024 Final draft guidance
13 February 2024 Invitation to participate
14 September 2023 - 12 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6306
03 August 2023 In progress. DHSC referral received
07 June 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual